Moving to Germany
We started in Germany, but we have offices all over the world.
Search
Innovation from within
Justine Rochon and Marc Weimer talk about the transformation of Biostatistics and Data Sciences (BDS) into a modern organisation in drug development.
Partnering Interests
Partnering Interests
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care
Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care
Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation
Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation
Help in all situations in life
Boehringer Ingelheim focuses on the wellbeing of its employees – and is therefore also a "Global Top Employer 2023".
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
Data Show Safety of Pradaxa® (dabigatran etexilate) in Children | Boehringer Ingelheim US
BI announces results from 2 pediatric studies of PRADAXA, presented at the ISTH Congress in Melbourne. View ISI, PI and Med Guide.
Boehringer Ingelheim Office Hours
Boehringer Ingelheim Office Hours
The Research Process
The Research Process
Six creative Connecticut students turn aspiring ideas into inventive innovation
Learn about the 2023 Connecticut Invention Convention winners.
FDA approves treatment option for T2D in children 10 and older
FDA has approved Jardiance® (empagliflozin) tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes. See Safety, PI & Med Guide.
New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism
New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism
Biosimilars
: A biosimilar is a version of a biologic medication that is made by a different company than the one that invented it, with no clinically meaningful differences in terms of safety, potency and purity.
Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
Biosimilars
Biosimilars
Family owned
Did you know that Boehringer is still family-owned? Read this article to learn more about our culture. Check out our Careers Page for more talent insights!
Our Work with the Gates Foundation | COVID-19 | Boehringer Ingelheim US
With global life science companies, we are joining the COVID-19 Therapeutics Accelerator of the Bill & Melinda Gates Foundation to fight the pandemic.
Planting Trees to Help Care for the Environment
Planting Trees to Help Care for the Environment
Welcome to the Neuroscience Gallery | Boehringer Ingelheim US
Click here to take a guided tour through our Neuroscience virtual 3-D art exhibition, helping us to improve how we diagnose and treat various diseases.
Recognizing Parents Supporting Other Parents
Recognizing Parents Supporting Other Parents
Our Responsibility
Our Responsibility
Empowering Employees to be Their Own Superheroes
Empowering Employees to be Their Own Superheroes
Taking patient centricity to new heights
Learn about how we focus on putting patients first and finding solutions to meet their healthcare needs.